Podcasts about idsa

IDSA CEO Jeanne Marrazzo, MD, MPH, FIDSA, hosts IDSA board members Ronald Nahass, MD, MHCM, FIDSA, Wendy Armstrong, MD, FIDSA, and Max Brito, MD, MPH, FIDSA, to discuss the challenges and opportunities shaping the field of infectious diseases. From defending vaccine science to strengthening the ID workforce and growing membership, the group shares how IDSA is responding to today's health care challenges and preparing for the future.

Jeff and Jim welcome back five-time guest Jeff Reich, Executive Director of the Identity Defined Security Alliance, just ahead of Identity Management Day 2026 on April 14th. Jeff walks through the structure of the 21-hour global event, this year's theme of Finding Identity: The Search for You, Me, and the Machines, and highlights from each regional program including a remarkable 11th grader presenting on cybersecurity and neuroscience. The conversation expands into AI guardrails, the growing obsolescence of traditional PAM, zero standing privilege as a long-term goal, the march toward a passwordless world through passkeys, and what quantum resilience actually means for practitioners today.Connect with Jeff: https://www.linkedin.com/in/jreich/Learn more about the Identity Defined Security Alliance: https://www.idsalliance.org/Connect with us on LinkedIn:Jim McDonald: https://www.linkedin.com/in/jimmcdonaldpmp/Jeff Steadman: https://www.linkedin.com/in/jeffsteadman/Visit the show on the web at http://idacpodcast.comTimestamps:00:00 Welcome and podcast life behind the scenes02:00 Identiverse 2026 updates and conference discount codes05:00 Introducing Jeff Reich, Executive Director of IDSA07:00 Identity Management Day: structure of a 21-hour global event11:00 Oceania and Asia region highlights13:30 EMEA highlights and powerhouse panelists from Copenhagen16:00 Americas region and the 11th grader presenting on cybersecurity20:00 Theme reveal: Finding Identity, The Search for You, Me, and the Machines23:30 AI and identity: guardrails, frameworks, and what organizations are missing28:30 Standing privilege is crumbling in the age of ephemeral workloads30:00 Is traditional PAM becoming obsolete?34:30 Zero standing privilege and the passkey journey40:30 Getting the fundamentals right before chasing the shiny tools46:30 Quantum computing, quantum resilience, and cryptocurrency risk53:00 Social engineering is still the biggest threat55:00 Identity Management Day theme song suggestionsKeywords:Identity Management Day 2026, IDSA, Identity Defined Security Alliance, Jeff Reich, IAM, non-human identities, machine identities, agentic identity, zero standing privilege, PAM, passkeys, quantum resilience, AI and identity, deepfakes, social engineering, IDAC, Identity at the Center, Jeff Steadman, Jim McDonald

No episódio de hoje do Check-up Semanal, o Dr. Ronaldo Gismondi, editor-chefe médico do Portal Afya e do Whitebook, comenta os principais destaques recentes em Infectologia publicados no Portal Afya.O programa aborda atualizações relevantes sobre tuberculose no Brasil, arboviroses emergentes, manejo de prostatite bacteriana, coinfecção TB-HIV e estratégias no tratamento de infecções por Pseudomonas aeruginosa.Artigos mencionados:Tuberculose no Brasil: o que o infectologista deve saber em 2026?Surto de Febre do Oropouche: estudo compara gravidade e sintomas com a dengueProstatite bacteriana: o que diz a nova revisão da IDSA?Uso de prednisona em pacientes hospitalizados com coinfecção TB-HIVComo manejar infecções difíceis de tratar por Pseudomonas aeruginosa?

No episódio de hoje do Check-up Semanal, o Dr. Ronaldo Gismondi, editor-chefe médico do Portal Afya e do Whitebook, comenta os principais destaques recentes em Infectologia publicados no Portal Afya.O programa aborda atualizações relevantes sobre tuberculose no Brasil, arboviroses emergentes, manejo de prostatite bacteriana, coinfecção TB-HIV e estratégias no tratamento de infecções por Pseudomonas aeruginosa.Artigos mencionados:Tuberculose no Brasil: o que o infectologista deve saber em 2026?Surto de Febre do Oropouche: estudo compara gravidade e sintomas com a dengueProstatite bacteriana: o que diz a nova revisão da IDSA?Uso de prednisona em pacientes hospitalizados com coinfecção TB-HIVComo manejar infecções difíceis de tratar por Pseudomonas aeruginosa?

Dr. John Fleetham chats with Dr. Sonal Munsiff and Dr. Raquel Duarte about their article, "Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline." 

Newly appointed IDSA CEO (and former NIAID Director) Jeanne Marrazzo, M.D., M.P.H., joins us this month to discuss a wealth of important topics that stand at the intersection of HIV research, clinical care, and policy/politics. We touch on highlights from the recent CROI 2026 science meeting — both in terms of the research and the vibes; on how the U.S. clinical community must adjust in the wake of cuts to both funding and trust in federal health agencies; on the role of IDSA, HIVMA, and other professional organizations in filling the void; and on the new era that's emerging for clinicians who seek to support their patients and colleagues during a turbulent sociopolitical time.   Read the transcript on TheBodyPro (every click helps!):   https://www.thebodypro.com/podcast/hiv/future-hiv-care-jeanne-marrazzo-croi-march-2026   The host and executive producer of this podcast is Myles Helfand; our senior production manager is Alina Mogollon-Volk; our senior producer is Lizzie Warren; our associate production manager is Maui Voskova; and our audio editor is Kim Buikema.

No episódio de hoje do Check-up Semanal, o Dr. Ronaldo Gismondi, editor-chefe médico do Portal Afya e do Whitebook, comenta os principais destaques recentes em Pediatria, com foco em anemia ferropriva, aleitamento em prematuros, manejo do derrame pleural e empiema, além de mudanças conceituais no crescimento infantil.Para mais conteúdos como esse, acompanhe nosso canal no Spotify!Leia na íntegra os artigos mencionados hoje:SBP 2026: Recomendações para prevenção e tratamento da anemia ferroprivaAAP atualiza diretrizes sobre aleitamento para RN muito baixo pesoNova diretriz aborda derrame pleural na pneumonia infantil pela IDSA e PIDS – Drenar ou observar?Nova diretriz publicada IDSA e PIDS aborda a conduta no empiemaNova diretriz da AAP e da NASPGHAN exclui o termo “failure to thrive”

Send a textIn this episode of Never Been Sicker, Michael Rubino sits down with Scott Forsgren (Better Health Guy) to unpack what actually helps people recover from complex chronic illness. Scott shares his 30-year journey that began with a tick bite, years of severe symptoms, and 45 doctors before finding answers in Lyme and co-infections, and later, mold exposure.Together, they break down why “kill, kill, kill” protocols often fail, why symptoms overlap across mold, Lyme, metals, and immune dysregulation, and what Scott sees as the true foundations of healing: nervous system regulation, mast cell stability, detox and drainage support, and addressing the external environment.They also dig into controversies around urine mycotoxin testing, ERMI interpretation, and why you may improve while living in exposure, but you typically won't fully recover until the environment is addressed.Chapter markers00:00 Intro00:44 Scott's health story begins (tick bite, sudden symptoms)02:47 First real breakthrough: Lyme and co-infections04:51 What Scott would do differently07:14 Moving beyond “kill, kill, kill”10:03 Can symptoms tell you it's mold?12:20 Why we've never been sicker17:00 Biggest mistakes after diagnosis20:36 The foundational steps to healing34:02 Can you heal while living in exposure?38:33 Urine mycotoxin controversy41:58 ERMI, HERTSMI-2, and interpretation50:04 Mycotoxins, spores, fragments, and why “killing” is not enough56:26 The biggest lie: the label59:28 ILADS vs IDSA and what's true on both sides01:03:02 Where to find Scott + final hope message01:06:10 Outro-----------------------------------------------------------------------------------------------

Canadian energy firm Enbridge will reimburse a northern Wisconsin county for the cost of policing protests expected with construction of the company's Line 5 reroute. As Danielle Kaeding reports, the Ashland County board approved the deal Tuesday. The Wisconsin Counties Association negotiated an agreement where Enbridge will reimburse local governments for public safety costs tied to the Line 5 project in northern Wisconsin. Funds will be deposited into an escrow account managed by the association. Some residents worried the deal would turn local authorities into a private security force. Bad River tribal member Edith Leoso warned against signing the agreement to get reimbursed by Enbridge. “They will feed you what you want to hear, and then they will take everything from this area and leave you to pick up the pieces.” An Enbridge spokesperson said the company volunteered to fund the account. Enbridge also said it received a final US Army Corps permit that the company says will allow construction to move forward, but state approvals for the project are being challenged in court. Enbridge previously paid millions for public safety costs tied to protests of its Line 3 replacement project in Minnesota. ZenniHome founder Bob Worsley shares his excitement about opening up his facility in 2024 atop the former Navajo Generating Station near Page, Ariz. (Photo: Gabriel Pietrorazio / KJZZ) A civil lawsuit filed in Maricopa County Superior Court in Arizona alleges a factory on the Navajo Nation was “squandering millions on improper and mysterious expenditures” before suddenly shutting down in July. KJZZ's Gabriel Pietrorazio has more. The Albuquerque, N.M.-based firm Indigenous Design Studio + Architecture (IDSA) alleges that Mesa subcontractor ZenniHome breached its $50 million deal to build 160 modular homes. “There's a whole lot of money that got dumped into Zenni and obviously only to produce 18 homes, it's a mystery how that occurred.” Attorney Jay Curtis says IDSA is looking to repair the reputation of its founder, Tamarah Begay, in addition to recouping roughly $22 million from the American Rescue Plan Act for the Navajo Nation. ZenniHome CEO Bob Worsley says there will not be a refund of any amount. “No, the money is gone … It's not sitting in somebody's account somewhere, so the company has been liquidated. There's no more assets. It's just almost theater when we spent every dime they gave us, and about $4 million more than that – out of my pocket – so yeah, that's not going to happen.” Worsley also faces a separate federal class action lawsuit after laying off more than 200 employees last year. Rex Lee Jim, Vice President of the Navajo Nation prepares notes prior to a media call in the U.S. Department of Agriculture (USDA) Radio Studio in Washington, D. C., Monday, March. 3, 2015. (Photo: Bob Nichols / USDA) Former Navajo Nation Vice President Rex Lee Jim is being remembered for his advocacy for Navajo people, including in education and culture, and as an international diplomat. Jim served as vice president from 2011 to 2015 with Navajo President Ben Shelly. He also served on the Navajo council, was a poet, playwright, author, and traditional medicine man. The Navajo Nation Council said Jim passed away on Tuesday and recognized his dedication to Navajo people, cultural preservation, and global Indigenous advocacy. JoAnn Chase (Mandan, Hidatsa, and Arikara), former executive director of the National Congress of American Indians (NCAI), is being remembered for strengthening NCAI's national presence and advocating for Native rights. Chase served as executive director from 1994 to 2001. In a statement Tuesday, NCAI said of Chase's passing that her leadership help the organization become stronger and more visible, working with tribal leaders, Congress, and others. She later worked in philanthropy, policy, and arts, including most recently serving as vice chair of the board for the Southwestern Association for Indian Arts. Get National Native News delivered to your inbox daily. Sign up for our daily newsletter today. Download our NV1 Android or iOs App for breaking news alerts. Check out today’s Native America Calling episode Wednesday, February 25, 2026 — The Menu: Commod Bods, a standout frybread stand, and Afro-Indigenous mutual aid in Minneapolis

In this third collaboration between SIDP's Breakpoints and ESCMID's Communicable podcasts, hosts Erin McCreary and Angela Huttner invite two veteran authors of guidelines and guidances, Pranita Tamma (Philadelphia, USA) and Benedikt Huttner (WHO, Geneva, Switzerland) [1-3]. Together, they deconstruct the complex landscape of developing and implementing guidelines into digestible components: they discuss why different organizations develop guidelines and what need they hope to fulfil, the framework including the GRADE methodology under which guidelines are written, and major barriers in the uptake of guidelines. The conversation also details the distinction between guideline and guidance as well as the art and science behind formulating recommendations or suggestions, with a few anecdotal cases sprinkled in from the panel. References 1. WHO handbook for guideline development, 2nd Edition, https://www.who.int/publications/i/item/9789241548960 2. The WHO AWaRe (Access, Watch, Reserve) antibiotic book https://www.who.int/publications/i/item/9789240062382 3. IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections, https://www.idsociety.org/practice-guideline/amr-guidance/ Learn more about the Society of Infectious Diseases Pharmacists: https://sidp.org/About Twitter: @SIDPharm (https://twitter.com/SIDPharm) Instagram: @SIDPharm (https://www.instagram.com/sidpharm/) Facebook: https://www.facebook.com/sidprx LinkedIn: https://www.linkedin.com/company/sidp/ SIDP welcomes pharmacists and non-pharmacist members with an interest in infectious diseases, learn how to join here: https://sidp.org/Become-a-Member Listen to Breakpoints on iTunes, Overcast, Spotify, Listen Notes, Player FM, Pocket Casts, Stitcher, Google Play, TuneIn, Blubrry, RadioPublic, or by using our RSS feed: https://sidp.pinecast.co/

In this third collaboration between SIDP's Breakpoints and ESCMID's Communicable podcasts, hosts Erin McCreary and Angela Huttner invite two veteran authors of guidelines and guidances, Pranita Tamma (Philadelphia, USA) and Benedikt Huttner (WHO, Geneva, Switzerland) [1-3]. Together, they deconstruct the complex landscape of developing and implementing guidelines into digestible components: they discuss why different organizations develop guidelines and what need they hope to fulfil, the framework including the GRADE methodology under which guidelines are written, and major barriers in the uptake of guidelines. The conversation also details the distinction between guideline and guidance as well as the art and science behind formulating recommendations or suggestions, with a few anecdotal cases sprinkled in from the panel. This episode was edited by Kathryn Hostettler and Lacy Worden. It was peer reviewed for Breakpoints by Lacy Worden and for Communicable by Ljiljana Lukić of University Hospital for Infectious Diseases in Zagreb, Croatia.  References WHO handbook for guideline development, 2nd Edition The WHO AWaRe (Access, Watch, Reserve) antibiotic book IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative InfectionsFurther readingESCMID AMR Guidelines, https://clinicalmicrobiologyandinfection.com/retrieve/pii/S1198743X21006790 GRADE working group, https://www.gradeworkinggroup.org/GRADE Book, https://book.gradepro.org/ IDSA's intraabdominal guidelines, https://www.idsociety.org/practice-guideline/intra-abdominal-infections/ ESCMID Manual for Clinical Practice Guidelines and Other Guidance Documents, https://www.escmid.org/guidelines-journals/guidelines/ International Consensus Guidelines for the Optimal Use of the Polymyxins https://accpjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/phar.2209 American Thoracic Society guidelines on community-acquired pneumonia, https://www.atsjournals.org/doi/abs/10.1164/rccm.202507-1692ST 

Access Transcript | Access Slides | Obtain Credit | For More Information    …

Mary Beth Pfeiffer, the pioneering investigative journalist who transformed national understanding of Lyme disease, joins the Tick Boot Camp Podcast for a landmark conversation. Before her work, Lyme disease was widely dismissed as rare, mild, and easily treated. After her reporting, that narrative collapsed. Through her award-winning journalism and her groundbreaking book Lyme: The First Epidemic of Climate Change, she became the first major voice to expose the truth: Lyme disease is a global, climate-driven epidemic that is chronically misdiagnosed, dangerously underestimated, and systematically mishandled by mainstream medicine. In this interview, Mary Beth shares how her earlier investigative work on mental illness in U.S. jails prepared her to recognize patterns of institutional failure within the Lyme disease system. For decades, she documented how people with bipolar disorder and schizophrenia were misunderstood, punished, or dismissed by the very institutions meant to protect them. When she turned her attention to Lyme in 2012, she immediately recognized the same dynamic: patients with neurological and psychiatric manifestations were told they were anxious, depressed, or “crazy,” rather than infected. Families were blamed, symptoms were minimized, and children were left to suffer. Her background gave her a rare lens into how biological illness becomes mislabeled as psychological and how systems silence the very people who need help. Mary Beth explains how her investigative series for the Poughkeepsie Journal went viral worldwide, surprising even her editors. Her reporting was read in all 50 states and across Europe and Australia, prompting the CDC to contact her directly. She details what she uncovered through Freedom of Information Act requests, including internal emails between NIH and CDC officials referring to patients as “Lyme loonies” and framing the situation as a “war” against advocates. These documents revealed attitudes inside the highest levels of public health that shaped decades of policy, diagnostic guidelines, and patient care. The conversation dives into how a small group of early Lyme researchers defined the disease in the 1980s and then used their influence to control medical journals, shape NIH grant funding, and enforce rigid IDSA treatment guidelines. As Mary Beth explains, these early assumptions—often based on limited data and flawed antibody tests—became dogma. Their conclusions created an ecosystem where only short-course antibiotics were considered acceptable, chronic symptoms were dismissed, and doctors who treated beyond the guidelines were punished by medical boards. The result was a generation of patients abandoned by the system, forced to self-fund care, travel to distant specialists, and in many cases bankrupt themselves in search of answers. Mary Beth discusses how patients became her greatest teachers. She shares emotional stories, including children who lost years of their lives, athletes whose careers were derailed, and an 11-year-old boy misdiagnosed for so long he ended up in a hospital bed in his living room before finally being rescued by Dr. Charles Ray Jones. She describes support groups filled with people who had seen five, ten, or fifteen doctors and were told their symptoms were anxiety, depression, or “anything but Lyme.” The interview covers the scientific evidence supporting Lyme persistence, including animal studies, autopsy tissue findings, and molecular research showing Borrelia surviving standard treatment. Mary Beth explains why the two-tier antibody test has failed generations of patients, why indirect antibody tests are inherently flawed for immune-dysregulated populations, and why the future of accurate diagnosis depends on direct detection methods. She highlights emerging technologies, including promising work by Aces Diagnostics and Researcher Holly Ahern, which may finally offer accurate testing across all stages of infection. The conversation moves into the larger systemic problem: how money, insurance policies, medical boards, industry influence, and journal gatekeeping have shaped what doctors are allowed to do. Mary Beth and the Tick Boot Camp team explore why clinicians who try to help chronic Lyme patients often lose insurance coverage, face board complaints, or have their licenses threatened. They discuss how electronic monitoring, AI systems, and corporate-owned medical practices further restrict doctors from practicing individualized, patient-centered medicine. The second half of the interview focuses on the environmental drivers behind the explosion of Lyme disease. Mary Beth explains how warming temperatures, shorter winters, and ecological fragmentation have created ideal habitats for ticks. She describes how ticks have climbed mountains, expanded into higher latitudes, colonized suburban landscapes, and gained longer active seasons. These environmental changes, combined with human development patterns, have dramatically increased opportunities for exposure. She also addresses public interest in the bioweapons question raised by Chris Newby's book Bitten, explaining why historical documentation and FOIA evidence convinced her that military tick experiments occurred, even if their impact on today's epidemic is still unknown. The episode closes with Mary Beth's reflections on prevention, vigilance, and the psychological cost of losing the innocence of nature. She describes how she now sees fields, forests, and even yards differently and why she teaches her grandchildren to treat nature with both respect and caution. She shares her hope for the future: better diagnostics, more independent research, journalists willing to challenge medical orthodoxy, and a cultural shift that frees doctors to practice real medicine rather than rigid algorithms. This interview is essential listening for anyone affected by Lyme disease, anyone questioning why chronic illness is so often dismissed, and anyone seeking to understand how climate change, medical politics, and investigative journalism intersect in one of the most important health crises of our time.

The Interdisciplinary Meeting of Antimicrobial Resistance and Innovation has launched! The first version of IMARI brought together researchers, clinicians, industry leaders and policymakers to address one of the greatest challenges in modern medicine: antimicrobial resistance" Check the highlights at IMARI.org and prepare for IMARI 2017 from January 27-29, 2027! The inaugural amazing conference took place in Las Vegas. This is the forst time that ASM and IDSA collaborate together in a scientific meeting. One of the sessions involved an unprecedent collaboration between two journals AAC and JID published by each society. To celebrate this achievement we had a session of the best AMR papers of 2025 for AAC and JID. This session will be presented here as apart of our series.  Watch this episode: https://youtu.be/XRYl7863z34 Objectives: - Review the best papers and topics of AMR in 2025 form AAC and JID. - Discuss the context of each finding and contributions to the AMR community - Elaborate on the implications for AMR, novelties and how the field is advancing. Guests:  - Ayesha Khan, Ph.D.  Assistant Professor, Pathology & Laboratory Medicine and Associate Director, Division of Clinical Microbiology Biomedical & Translational Research Track. Principal Investigator, UC3P UCI Prime Pre-Health Pathways Program. - Madison Stellfox, M.D. Ph.D. Assistant Professor of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA.  Links:  Links: AAC A microbiological and structural analysis of the interplay between sulbactam/durlobactam and imipenem against penicillin-binding proteins (PBPs) of Acinetobacter spp. https://doi.org/10.1128/aac.01627-24 JID Ampicillin/Sulbactam in Combination with Ceftazidime/Avibactam Against Metallo-β-Lactamase-Producing Carbapenem-Resistant Acinetobacter baumannii: A Genomics-Informed Mechanism-based model https://doi.org/10.1093/infdis/jiaf567 AAC Advancements in the fight against globally distributed OXA-48 carbapenemase: evaluating the new generation of carbapenemase inhibitors https://doi.org/10.1128/aac.01614-24 JID Daptomycin-Loaded Nanocarriers Facilitate Synergistic Killing of Methicillin-Resistant Staphylococcus aureus via Lipid-Mediated Interactions and Targeting https://doi.org/10.1093/infdis/jiaf492 AAC Amoxicillin-non-susceptible Streptococcus pneumoniae causing invasive pneumonia: serotypes, clones, and clinical impact https://doi.org/10.1128/aac.00237-25 JID Blood Cultures Contain Populations of Genetically Diverse Candida albicans Strains that May Differ in Echinocandin Tolerance and Fitness https://doi.org/10.1093/infdis/jiaf495 AAC Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains https://doi.org/10.1128/aac.00137-25 JID Engineered Mycobacteriophage TM4::GeNL Rapidly Determines Bedaquiline, Pretomanid, Linezolid, Rifampicin, and Clofazimine Sensitivity in Mycobacterium tuberculosis Clinical Isolates https://doi.org/10.1093/infdis/jiae438 AAC Emergence of antibiotic-specific Mycobacterium tuberculosis phenotypes during prolonged treatment of mice https://doi.org/10.1128/aac.01310-24 JID The Changing Paradigm in Infectious Diseases—Host-Directed Medicine: Implications for the Next Generation of ID Physicians https://doi.org/10.1093/infdis/jiaf497 JID Triggering Toll-Like Receptor 5 Signaling During Pneumococcal Superinfection Prevents the Selection of Antibiotic Resistance https://doi.org/10.1093/infdis/jiae239 IMARI Conference This episode is brought to you by the Antimicrobial Agents and Chemotherapy journal available at https://asm.org/aac.  If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit https://asm.org/joinasm to sign up. Visit https://asm.org/aac to browse issues and/or submit a manuscript. Follow Cesar on twitter at https://twitter.com/SuperBugDoc for AAC updates. 

In this episode of The ICHE Podcast, host Dr. David Calfee speaks with the authors of the newly released Multisociety Guidance for Infection Prevention and Control in Nursing Homes. He is joined by Dr. Lona Mody, Dr. Deborah Burdsall, Dr. Susan Huang, Dr. Robin Jump, and Dr. Rekha Murthy to discuss the development, key updates, and practical implications of this comprehensive guidance. Developed by SHEA in collaboration with APIC, IDSA, PALTmed, and the American Geriatrics Society, the guidance document updates the earlier SHEA/APIC guideline: Infection prevention and control in the long-term care facility published in July 2008. The authors walk through how the updated guidance reflects current evidence and lessons learned, offering a flexible framework to help nursing homes prevent and control infections while preserving the social, rehabilitative, and quality-of-life goals that are central to residential care. Links for this episode: https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/multisociety-guidance-for-infection-prevention-and-control-in-nursing-homes/88B28E99CD7FDB3668DDAE9C3D2184A0

Show notes at pharmacyjoe.com/episode1089 In this episode, I'll discuss a study that addresses the controversy over giving patients with viral infections antibiotics in the Community Acquired Pneumonia guidelines.

Listen in as experts Thomas P. Lodise, PharmD, PhD, and George Sakoulas, MD, FIDSA, explore tailored antibiotic strategies for diverse patients with acute bacterial skin and skin structure infections (ABSSSIs). Their insightful discussion focuses on antibiotic developments that followed publication of the IDSA practice guidelines in 2014 and the challenges unique to ABSSSIs, including a lack of determined bacterial etiology for many cases. PresentersThomas P. Lodise, PharmD, PhDProfessorAlbany College of Pharmacy and Health SciencesInfectious Diseases Clinical Pharmacy SpecialistStratton VA Medical CenterAlbany, New YorkGeorge Sakoulas, MD, FIDSAChief, Infectious DiseasesSharp Rees-Stealy Medical GroupAdjunct Professor of PediatricsUniversity of California San Diego School of MedicineSan Diego, CaliforniaLink to full program:https://bit.ly/4oIKwzsGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Join Ryan K. Shields, PharmD, MS, in the second of three recap podcasts taken from our live event, “The Plot (and Sputum) Thickens: Encountering Carbapenem Resistance in Critically Ill Patients.” Learn how to optimize antimicrobial regimens and develop evidence-based antibiotic management plans for complex infections caused by carbapenem-resistant bacteria. Topics covered in this segment include:The diverse mechanisms of β-lactam resistanceThe effect of resistance mechanisms on susceptibility to antimicrobials 2024 IDSA guidance for treatmentConsiderations for antibiotic selectionThe role of combination therapyPresenter:Ryan K. Shields, PharmD, MS Associate Professor of MedicineCo-Director, Center for Innovative Antimicrobial TherapyUniversity of PittsburghCo-Director, Antibiotic Management ProgramUPMC Presbyterian HospitalPittsburgh, PennsylvaniaLink to full program and downloadable slides:CCO: https://bit.ly/3LXzateProCE: https://bit.ly/3Mjao6GGet access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Join Ryan K. Shields, PharmD, MS, in the third of 3 podcasts from our live event, “The Plot (and Sputum) Thickens: Encountering Carbapenem Resistance in Critically Ill Patients” to learn how to optimize antimicrobial regimens and develop evidence-based antibiotic management plans for complex infections caused by carbapenem-resistant bacteria. Topics covered in this segment include:Mechanisms of resistance in S. maltophiliaCurrent frontline therapies2024 IDSA guidance for treatmentPresenter:Ryan K. Shields, PharmD, MS Associate Professor of MedicineCo-Director, Center for Innovative Antimicrobial TherapyUniversity of PittsburghCo-Director, Antibiotic Management ProgramUPMC Presbyterian HospitalPittsburgh, PennsylvaniaLink to full program and downloadable slides:https://bit.ly/3JWaqRvGet access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Communicable, Erin McCreary and Angela Huttner are joined by Barbara Trautner (St. Louis, USA) and Valéry Lavergne (Vancouver, Canada), the co-chairs and leading authors of the first IDSA guideline on complicated urinary tract infection (cUTI), which was published a few months ago [1]. Together, they discuss the process of developing the guideline from its conception in 2018, the new definition of cUTI, their stepwise approach to clinical decision-making, and some case-by-case scenarios for common antibiotics. They also elaborate on how this guideline compares (and contrasts) to other existing UTI guidelines—including the previous IDSA guideline for UTI [2] —and the clinical need to supply frontline clinicians to identify and distinguish complicated cases from the uncomplicated ones. The episode closes with what essential clinical questions the guests hope to tackle next.  This episode was edited by Kathryn Hostettler and peer reviewed by Maria Ana Flores of Santa Maria Local Health Unit, Lisbon, Portugal.Other resources:European Urologic Association guidelinesUpToDateFDA guidance on complicated UTI ReferencesTrautner BW, et al. Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections Gupta, K, et al. Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: 2010 Update by IDSA

Show notes at pharmacyjoe.com/episode1067. In this episode, I'll discuss recent guidelines about complicated UTI treatment. The post 1067: The IDSA's 4 Step Approach to Choosing Empiric Therapy to Treat Complicated UTI appeared first on Pharmacy Joe.

In this episode of Better Edge, Jennifer Miles-Thomas, MD, moderates a thoughtful conversation with Anthony Schaeffer, MD, discussing complicated urinary tract infections (cUTIs) and their management. Dr. Schaeffer, who contributed to the recent IDSA guidelines on cUTIs, emphasizes the need to understand underlying causes of recurrent infections rather than treating them as isolated events. The conversation explores critical topics such as antibiotic resistance, effective treatment strategies and the importance of early intervention in febrile cases.

About this Episode Episode 49 of “The 2 View” – New IDSA Complicated UTI Guidelines, Pediatric Nicotine OD, Hepatitis C Screening in the ED, High-Risk Delta Troponins Segment 1A – Pediatric Nicotine Ingestion Madelyn O, Hays HL, Kistamgari S, et al. Nicotine Ingestions Among Young Children: 2010–2023. Pediatrics. 2025;156(2):e2024070522. doi:10.1542/peds.2024-070522. Segment 1B – Finger Thoracostomy and Traumatic Pneumothorax/Hemothorax Blank, J, de Moya MA. Traumatic pneumothorax and hemothorax: What you need to know. J Trauma Acute Care Surg. Published online July 3, 2025. doi:10.1097/TA.0000000000004692 Beyer CA, Ruf AC, Alshawi AB, Cannon JW. Management of traumatic pneumothorax and hemothorax. Curr Probl Surg. 2025;63. doi:10.1016/j.cpsurg.2024.101707. Weingart, S. EMCrit 62 – Needle vs. Knife II: Needle Thoracostomy (Decompression)? EMCrit. Published online December 11, 2011. https://emcrit.org/emcrit/needle-finger-thoracostomy/ Lange C, Sharma M. Podcast #223 - ATLS Episode 4: Thoracic Trauma (Chapter 4). Total EM. October 27, 2020. https://www.totalem.org/emergency-professionals/podcast-223-atls-episode-4-thoracic-trauma-chapter-4 Segment 2A – Hepatitis C Screening in EDs Haukoos J, Rothman RE, Galbraith JW, et al. Hepatitis C Screening in Emergency Departments: The DETECT Hep C Randomized Clinical Trial. JAMA. 2025;334(6):497–507. doi:10.1001/jama.2025.10563 Segment 2B – Serial HS-Troponin Patterns Huggins C, Saltarell Ni, Swoboda TK, et al. Kinetic changes in high-sensitivity cardiac troponin for risk stratification of emergency department chest pain patients. Am J Emerg Med. 2025;93:176-181. doi:10.1016/j.ajem.2025.04.010. Segment 3 - Updated IDSA Guidelines on Complicated Urinary Tract Infections Splete H. IDSA Updates Guidelines on Complicated UTIS. Medscape. Published online July 18, 2025. https://www.medscape.com/viewarticle/idsa-updates-guidelines-complicated-utis-2025a1000j3l Trautner BW, Cortes-Penfield NW, Gupta K, et al. Complicated Urinary Tract Infections (cUTI): Clinical Guidelines for Treatment and Management. IDSA. Published online July 17, 2025. https://www.idsociety.org/practice-guideline/complicated-urinary-tract-infections/ Roberts M, Sharma M. 34 - Pertussis, Computer Interpretation of EKGs, Tuberculosis, Fluoroquinolone Side Effects. The 2 View. Published online April 10, 2024. https://2view.fireside.fm/34 Roberts M, Sharma M. 46 - Heat Stroke Tx, A New Virus, Oral Cephalosporins Vs Pyelo, Safe Discharges. The 2 View. Published online June 11, 2025. https://2view.fireside.fm/46 Bonus Reference – Ponytail Headache Blau JN. Ponytail Headache: A Pure Extracranial Headache. Headache. 2004;44(5):411-413. doi: 10.1111/j.1526-4610.2004.04092.x. Recurring Sources Center for Medical Education. http://ccme.org The Proceduralist. http://www.theproceduralist.org The Procedural Pause. https://journals.lww.com/em-news/blog/theproceduralpause/pages/default.aspx The Skeptics Guide to Emergency Medicine. http://www.thesgem.com Be sure to keep tuning in for more great prizes and fun trivia questions! Once you hear the question, please email us your guesses at 2viewcast@gmail.com and tell us who you want to give a shout-out to.

Have you had symptoms return after stopping Lyme treatment? Share your story below. Your experience may help someone else navigating the same difficult decision.SummaryOne of the most frequent questions in Lyme care is: “If I feel better, should I stop treatment?” The answer is complicated. While no one wants to stay on antibiotics longer than necessary, stopping too soon often leads to relapse.Lyme disease is not a typical infection. Borrelia burgdorferi can persist by hiding in tissues, forming biofilms, and shifting into alternate forms. When treatment ends prematurely, surviving bacteria may re-emerge, and symptoms such as brain fog, joint pain, fatigue, or neuropathy often return. Co-infections like Babesia or Bartonella add another layer, sometimes becoming more obvious once Lyme therapy is withdrawn.Guidelines remain divided. IDSA discourages extended therapy, while ILADS—where I helped author the 2004 and 2014 guidelines—supports individualized, carefully monitored treatment when patients remain ill. The key is shared decision-making, weighing risks and benefits, and avoiding a one-size-fits-all approach.The goal is not indefinite treatment, but the minimum effective therapy that allows patients to heal and reclaim their lives. The takeaway is simple: stopping Lyme treatment too soon often means starting over. Recovery is about staying better tomorrow—not just feeling better today.

“Has your family faced challenges with Lyme disease treatment for kids? Share your story in the comments—because until children are included in research, parents' voices are one of the most powerful tools we have. ..No NIH-funded Lyme treatment trials have included children under 18. Yet kids often present differently than adults—showing fatigue, mood or school changes, rather than joint pain. Their developing immune and nervous systems also process infection and medication uniquely.Because guidelines rely on adult data, children risk being dismissed or undertreated. Some relapse if therapy ends too soon, while others improve only when co-infections are addressed.Bottom line: pediatric Lyme requires individualized, flexible care until research finally includes children...#LymeDisease #LymeTreatment #PediatricLyme #LymeAwareness #ChildHealth #LymeWarrior #ChronicLyme #InvisibleIllness #ParentVoices

Dominate C. diff! Learn to distinguish colonization from infection, select first-line therapies, and counsel patients on recurrence prevention and microbiome recovery. We're joined by IDSA past president and expert on foodborne and intestinal infections, Dr. Cindy Sears (Johns Hopkins University) for a comprehensive update on Clostridioides difficile (C. diff, Cdiff, CDAD, CDI). Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments 00:00 Intro 03:00 Guest bio and hobby 04:25 Case of Charles Fleur Fontaine 06:00 Risk factors and epidemiology 08:00 Antibiotic hierarchy of risk 10:00 Diagnosis, testing strategies 14:00 Defining severity 17:30 Treatment options 20:00 Microbiome recovery strategies 24:00 Probiotics and postbiotics 27:00 Infection control counseling 30:00 C. diff and colon cancer 32:00 Recurrent C. diff strategies 35:00 Why some FMT and bezlotoxumab were discontinued 38:00 Microbiota replacement therapies 43:00 Prophylaxis strategies 45:00 Future therapies and ongoing research 47:00 Audience Q&A 52:00 Outro Credits Written and Produced by: Matthew Watto, MD, FACP  Cover Art and Infographic by: Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Sai S Achi MD,MBA,FACP Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Cynthia Sears MD Disclosures Dr. Sears reports no relevant financial disclosures. Dr. Williams financial relationships disclosed include a Merck grant or research support. This relationship has not ended. Sponsor: Mint Mobile  This year, skip breaking a sweat AND breaking the bank. Get this new customer offer and your 3-month Unlimited wireless plan for just 15 bucks a month at mintmobile.com/CURB  Sponsor: Panacea Financial Let Panacea Financial take the financial stress off your plate,so you can get back to doing what matters most. Visit panaceafinancial.com  Sponsor: FIGS Get15% off your first order at wearfigs.com with the code FIGSRX

She walked away from two decades of luxury bag design to build carbon-negative, vegan bags that actually make a difference. Meet Alona Komsky, co-founder of AKKONIQ, the minimalist bag brand that's reshaping sustainable fashion with innovation, function, and style.In this episode of the Conscious Design Podcast, host Ian Peterman explores how Alona turned her frustration with fast fashion and greenwashing into a mission: designing eco-friendly bags made from 3D-woven recycled materials, biodegradable fibers, and honest minimalist design.If you're interested in ethical fashion, sustainable materials, slow fashion, or how to build a conscious product brand—this episode is for you.⏩ Jump to your favorite parts: 00:52 - Meet Alona Komsky: Co-Founder of Akkoniq01:03 - The Journey to Sustainable Design02:06 - Challenges in the Industry05:00 - Creating Sustainable Bags14:30 - Innovative Materials and Techniques17:10 - Customer Feedback and Education26:38 - The Future of Sustainable Design27:50 - Conclusion and Contact InformationAbout Alona Komsky & AKKONIQAKKONIQ is a new name in sustainable fashion, but co-founder Alona Komsky brings over 20 years of award-winning design experience across tech, travel, and fashion. Her products have won Red Dot, IDSA, and remain global bestsellers.AKKONIQ blends minimalist aesthetics, functional innovation, and planet-first materials. Born from Alona's mission to align design with values, the brand delivers truly sustainable bags—without compromise or greenwashing.

In this episode of The Association Insights Podcast, we continue our July series on sponsorships, partnerships, and non-dues revenue with a behind-the-scenes look at how one major association is building long-term value through strategic partnerships and innovative fulfillment models.Host Meghan Henning sits down with John Buckley, Senior Director of Business Partnerships and Expo Operations at the Infectious Diseases Society of America (IDSA), to explore how IDWeek has evolved into a flagship experience that delivers for both members and industry partners.With nearly 20 years of experience in nonprofit event strategy, John shares how trust, creativity, and a long-game mindset have transformed IDSA's non-dues revenue approach—from tailored sponsorships to citywide visibility campaigns.

A common description of antibiotic action aims to classify them between “bactericidal” or “bacteriostatic”. Although these phenomena have robust in vitro foundations, the clinical translation of these concepts is sometimes difficult to ascertain. This controversial topic has important conceptual ramifications to treat severe infections. Today, we will discuss this topic with an expert in field.  Watch the video version here: https://youtu.be/3z4BItBrzbk Topics discussed: The definitions of “cidal” vs “static” antibiotics The clinical applicability of the above terms in terms of antibiotic choice and syndromatic approaches antibiotic choices and the controversy between bactericidal and bacteriostatic antibiotics.  Guest: Brad Spellberg, MD.  Chief Medical Officer at the Los Angeles General Medical Center  Links: ASM and IDSA launch the Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) in 2026 Watch this session on YouTube This episode is brought to you by the Antimicrobial Agents and Chemotherapy Journal.  Visit asm.org/aac to browse issues and/or submit a manuscript. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/joinasm to sign up.

Lyme Disease Wars is a term used to acknowledge that theapproach to handling this very serious condition is highly disputed. It's afrustrating subject for me, and I want to share with you some of the realfacts. Today, I'm not talking about pathophysiology. I'm focusing on treatmentand therapy options, and I refer to numerous studies, articles, and other research that you can use the following links to discover for yourself.If you have suffered from Lyme Disease and need more options for recovery, please visit www.laureltreewellnessllc.com to get started.Listed in this episode are the following references:​Medical Gaslighting and Lyme Disease​International Lyme and Associated Diseases Society​Global Lyme Alliance statement on the CDC update​NC Lyme Disease Foundation statement on the CDC update​CDC's current opinion on Chronic Lyme Disease​Article published by Infectious Disease Clinics of North America June 2015 on Chronic Lyme Disease​Frequency of bull's eye rash, as reported by CDC​Article published by IDCNA June 2008​Article by National Institute of Allergy and Infectious Diseases on Lyme Disease November 2018​Lyme Disease in Psychiatry, an article published in Psychiatric Times, 2022.​IDSA's 2025 analysis of clinics offering treatments for Lyme Disease​Time Magazine article on Chronic Lyme Disease, May 2024​John Hopkins study on the effects of Lyme on the brain, 2022​Article about the effects of Lyme on the brain, published in the American Journal of Psychiatry, 1994​Another article by the same author in the same journal, 2021​An article about the relationship of Lyme Disease and Alzheimer's, published in Nature, 2020​Another article about Lyme Disease and Alzheimer's, published in 2022​A PLOS One Journal article about how Lyme Disease impacts the brain, 2020.​Maine taking part in new studies on Lyme Disease

On episode #80 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 4/24/25 – 5/7/25. Hosts: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Incidence and Timing of Epstein–Barr Virus Whole Blood DNAemia in Epstein–Barr Virus-Mismatched Adult and Pediatric Solid Organ Transplant Recipients (Transplant Infectious Disease) Infant Respiratory Syncytial Virus Immunization Coverage in the Vaccine Safety Datalink: 2023–2024 (American Academy of Pediatrics) Impact of Nirsevimab on RSV and Non-RSV Severe Respiratory Infections in Hospitalized Infants (Influenza and other respiratory viruses) Hospital admissions of respiratory infections in infants plungewith nirsevimab RSV antibody (CIDRAP) Time to antiviral treatment in mild–moderate COVID-19 in the emergency department (Internal and Emergency Medicine) Delays in COVID antiviral receipt raised risk of poor outcomes after ED visits by 18%, data suggest (CIDRAP) Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV (MMWR) Bacterial Validation and clinical implementation of cerebrospinal fluid C-reactive protein for the diagnosis of bacterial meningitis (LANCET: Regional Health) Bridging to transplant: TDM-Guided Outpatient Dalbavancin Therapy in Chronic Granulomatous Disease with deep-seeded Inoperable Abscesses over 11 Months (OFID) Nitrites for Urinary Tract Infection—Time to Say Goodbye? (JAMA: Internal Medicine) Fungal The Last of US Season 2 (YouTube) High Mortality and Associated Risk Factors in Kidney Transplant Recipients with Cryptococcosis – A Nationwide Cohort Study Over a Decade Using USRDS Data (OFID) Use of Dog Serologic Data for Improved Understanding of Coccidioidomycosis (JID) Parasitic Performance of a novel P. falciparum rapid diagnostic test in areas of widespread hrp2/3 gene deletion (CID) Prevalence of Anopheles stephensi in the Horn of Africa: a systematic review and meta-analysis (BMC Infectious Diseases) Raising awareness of Demodex mites: a neglected cause of skin disease (Infection) Miscellaneous Scientific Integrity Under Threat: The Role of the IDSA, PIDS, and SHEA Journals in an Evolving Political Landscape (CID) Reasoning on Rounds Volume 2: a Framework for Teaching Management Reasoning in the Inpatient Setting (Journal of General Internal Medicine) Billing for and documentation of provider-to-provider interprofessional consults in infectious diseases (Journal of the Pediatric Infectious Diseases Society) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

In the last decade, there have been major changes in the approach of the treatment of pneumonia, in particular, with the availability of new diagnostic tools. Additionally, new drugs have been approved for the treatment of pneumonia. We discuss the approach to the management of pneumonia with a person who has spent most of his professional career working on this topic. Topics discussed: Definitions and nomenclature of pneumonia and evolution of these terms Changes in the diagnosis of pneumonia Ttherapeutic changes and future approaches for the treatment of pneumonia. Guest: Daniel M Musher, M.D. Links: ASM and IDSA launch the Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) in 2026 This episode is brought to you by the Antimicrobial Agents and Chemotherapy Journal.  Visit asm.org/aac to browse issues and/or submit a manuscript. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/joinasm to sign up.

Join Jeff and Jim in this episode of the Identity at the Center Podcast as they delve into the upcoming Identity Management Day 2025. Featuring guest Jeff Reich, Executive Director at the Identity Defined Security Alliance (IDSA), this episode unpacks the significance of non-human identities, AI in identity management, and the existential questions surrounding identity. The discussion covers upcoming events, awards, and what to expect from Identity Management Day, while also exploring the potential impact of Quantum Computing. Don't miss out on this in-depth conversation that combines humor with profound insights into the evolving landscape of identity management.Chapters00:00 Introduction and Identity Concerns01:30 AI and Podcasting01:59 AI Limitations and Future05:41 Conference Announcements07:30 Identity Management Day 202509:35 Global Identity Trends18:39 Existential Identity and AI27:29 The Concept of Identity in Technology28:05 Machine Identity and Its Implications29:30 Human vs. Machine Identity31:07 The Future of Identity with AI and Quantum Computing38:13 Identity Management Day Awards45:17 Fun and Lighthearted Discussion51:35 Conclusion and Final ThoughtsConnect with Jeff: https://www.linkedin.com/in/jreich/Learn more about the IDSA: https://www.idsalliance.org/Register for Identity Management Day 2025: https://www.accelevents.com/e/Identity-Management-Day-2025-Virtual-ConferenceConnect with us on LinkedIn:Jim McDonald: https://www.linkedin.com/in/jimmcdonaldpmp/Jeff Steadman: https://www.linkedin.com/in/jeffsteadman/Visit the show on the web at http://idacpodcast.comKeywords: Identity Management, AI, Non-Human Identities, Identity Defined Security Alliance, IDSA, Quantum Computing, Identity Management Day 2025, Identity at the Center Podcast.

ESCMID Global, ESCMID's flagship congress, kicks off this Friday in Vienna. In light of that, Angela Huttner and Thomas Tängdén sit down with ESCMID leadership, President Robert Skov and Immediate-Past President Annelies Zinkernagel in this episode of Communicable. Together they discuss the roles of medical societies like ESCMID in shaping healthcare policy, the importance of scientific communication, and lessons learned from the COVID pandemic. The conversation highlights ESCMID's priorities for the future on addressing antimicrobial resistance, fostering international collaboration and new educational initiatives. The episode also features personal anecdotes about what makes coming together at ESCMID Global so special. Tune in for a comprehensive look at how ESCMID is championing medical progress in infection for a healthier tomorrow.This episode was edited by Kathryn Hostettler and not peer reviewed.ReferencesGlobal impact of US policy changes: The ESCMID perspective. CMI Comms 2025;2(2): 105073.Malani AN, Sharland M, Clancy CJ, Skov R, ESCMID & IDSA Executive Boards. A global call to action to fight antimicrobial resistance: IDSA and ESCMID joint white paper. CMI Comms 2024; 1(2): 105033.Baghdadi JD & Morgan DJ. Diagnostic tests should be assessed for clinical impact. CMI Comms 2024; 1(2): 105010.

Dr. John Fleetham chats with Dr. Sonal Munsiff and Dr. Raquel Duarte about their article, "Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline." 

IT'S A BREAKPOINTS BREAKOUT!Jame and Callum are joined by the drugnamic duo of Julie-Ann Justo & Erin McCreary from the Breakpoints podcast to delve into the IDSA DTR Gram negative Guidance.Show notes for this episode are here.Breakpoints podcast can be found here: https://breakpoints-sidp.org/Lyrics: Tryin' to use some drugs to kill these bugsErin and Julie are PK PD thugs Gonna make these two ID:IOTS look like mugsIt's gonna be a Breakpoints BreakoutSorry the song sounds so tinny, Podcast host is doing something strange to it. Link to original MP3 here. Send us a textSupport the showQuestions, comments, suggestions to idiotspodcasting@gmail.com or on Bluesky @idiots-pod.bsky.socialPrep notes for completed episodes can be found here (Not all episodes have prep notes).If you are enjoying the podcast please leave a review on your preferred podcast app!Feel like giving back? Donations of caffeine gratefully received!https://www.buymeacoffee.com/idiotspod

On episode #75 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 2/13/25 – 2/26/25. Hosts: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral VIMKUNYA (FDA) Co-infection of SARS‐CoV‐2 and influenza A/B among patients with COVID-19(BMC Infectious Diseases) Measles (Texas Health and Human Services) 2025 Measles outbreak guidelines (New Mexico Health) BTN: Beyond the Noise with Paul Offit (microbeTV) Rubeola response (febrile) Timing of influenza antiviral therapy and risk of death in adults hospitalized with influenza-associated pneumonia, influenza hospitalization surveillance network (FluSurv-NET), 2012–2019 (CID) Mother-child dyads living with HIV in the Western Cape, South Africa: undetectable = undetectable? (Journal of the International AIDS Society) Early impacts of the PEPFAR stop-work order: a rapid assessment(Journal of the International AIDS Society) Prevalence, clinical management, and outcomes of adults hospitalised with endemic arbovirus illness in southeast Europe (MERMAIDS-ARBO): a prospective observational study (LANCET: Infectious Diseases) Bacterial Effects of extended anaerobic antibiotic coverage on anaerobic bloodstream infection: A multisite retrospective stud (International Journal of Infectious Diseases) The effectiveness of newer Beta-Lactams for the treatment of antimicrobial-resistant gram-negative meningitis (CID) Treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children: a aeta-analysis of macrolides versus tetracycline (The Pediatric Infectious Disease Journal) Fungal The Last of US Season 2 (YouTube) Concordance of noninvasive plasma cell-free DNA With invasive diagnostics for diagnosis of invasive fungal disease (CID) Invasive fungal infections in patients with liver disease: immunological and clinical considerations for the intensive care unit(Intensive Care Medicine) Parasitic Epidemiologic Investigation of Protozoa and soil-transmitted helminths in Starr County, Texas (American J Trop Med and Hyg) Post-artesunate delayed hemolysis in African children with severe malaria: incidence, medical impact and prevention (CID) Miscellaneous Telehealth (Medicare.gov) Public comment: IDSA guideline on management and treatment of complicated urinary tract infections (IDSA) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

30 years ago: Computer industry booms as consoles slump, Nintendo announces Ultra64 & The internet gets scary These stories and many more on this episode of the VGNRTM! This episode we will look back at the biggest stories in and around the video game industry in August 1994.  As always, we'll mostly be using magazine cover dates, and those are of course always a bit behind the actual events. Alex Smith of They Create Worlds is our cohost.  Check out his podcast here: https://www.theycreateworlds.com/ and order his book here: https://www.theycreateworlds.com/book Get us on your mobile device: Android:  https://www.google.com/podcasts?feed=aHR0cHM6Ly92aWRlb2dhbWVuZXdzcm9vbXRpbWVtYWNoaW5lLmxpYnN5bi5jb20vcnNz iOS:      https://podcasts.apple.com/de/podcast/video-game-newsroom-time-machine And if you like what we are doing here at the podcast, don't forget to like us on your podcasting app of choice, YouTube, and/or support us on patreon! https://www.patreon.com/VGNRTM Send comments on Mastodon @videogamenewsroomtimemachine@oldbytes.space Or twitter @videogamenewsr2 Or Instagram https://www.instagram.com/vgnrtm Or videogamenewsroomtimemachine@gmail.com Links: If you don't see all the links, find them here: https://www.patreon.com/posts/123352781/edit 7 Minutes in Heaven: Cliffhanger (Amiga) Video Version: https://youtu.be/KZ7J9qEpqxI     https://www.mobygames.com/game/29830/cliffhanger/ Corrections: July 1994 Ep - https://www.patreon.com/posts/july-1994-part-1-116538490         https://www.patreon.com/posts/july-1994-part-2-116538674 Ethan's fine site The History of How We Play: https://thehistoryofhowweplay.wordpress.com/     Defunctland Jim Henson Series - https://youtu.be/BVoGf1JTVeI?si=PBwUInz2t7hBe-Eq     https://en.wikipedia.org/wiki/Information_superhighway     https://en.namu.wiki/w/RX-78%20Gundam     https://fallout.fandom.com/wiki/SPECIAL     https://www.theycreateworlds.com/episodes/TCW164         https://en.wikipedia.org/wiki/Monte_Cook     Wrestling with Games - XBAND - https://youtu.be/k_5M-z_RUKA?si=tuuDxPGj6GnTPc-B     https://en.wikipedia.org/wiki/Steam_(service)               1994: Canada to get their own ratings     New VCR proves 6 heads are better than 1, The Toronto Star, August 11, 1994,Thursday, FINAL EDITION, Section: FAST FORWARD; Pg. F2, byline: BY ROBERT WRIGHT TORONTO STARON THE EDGE California presses forward with video game violence bill     https://www.retromags.com/files/file/3018-egm2-issue-02-august-1994/   pg. 29       https://www.latimes.com/archives/la-xpm-1994-04-13-mn-45306-story.html IDSA board selected     Mattel takes a second look at games     Mattel Hires Sega Executive, The Associated Press, August 2, 1994, Tuesday, BC cycle Square goes public     CORPORATE PROFILE: SQUARE, Jiji Press Ticker Service, AUGUST 5, 1994, FRIDAY Japanese companies playing with fire     "As derivatives proliferate, so do worries Companies try to control risks from transactions intended to rein in costs but which can backfire, The Nikkei Weekly (Japan), August 15, 1994, Section: FINANCE; Pg. 13, Byline: BY ASAKO ISHIBASHI Staff writer" Acclaim buys Valiant     ACCLAIM ACQUIRES VOYAGER COMMUNICATIONS FOR $65 MILLION Marks Company's Diversification into Comic Book Publishing, Business Wire, August 2, 1994, Tuesday     https://en.wikipedia.org/wiki/Comic_book_collecting#Bust_of_the_speculator_market UK video rental market embraces games... illegally     Games Spark Sagging U.K. Vid Biz; But Many Don't Have Licenses To Rent Them, Billboard, August 13, 1994, Section: HOME VIDEO; Pg. 76, Byline: BY PETER DEAN     Sonic out to zap the 'swapping' boom, The Scotsman, August 23, 1994, Tuesday, Byline: By Chris Mullinger UK teens tune out to games      MEDIA GUARDIAN: LUST FOR NASTIES AND HARD NEWS, The Guardian (London), August 8, 1994, Section: THE GUARDIAN FEATURES PAGE; Pg. T17      Sega announces US theme park     Universal Teams With Sega on Theme Park, Disneyland Annex Scaled Back, The Associated Press,  August 12, 1994, Friday, AM cycle, Section: Business News, Byline: By E. SCOTT RECKARD, AP Business Writer     Report: Sega Plan to Open 50 High-Tech Theme Parks in U.S., The Associated Press, August 16, 1994, Tuesday, BC cycle, Section: Business News Sega buys Data East Pinball     Sega acquires Data East Pinball, Business Wire, August 26, 1994, Friday Doom coming to arcades     DOOM IS ALL AROUND US, Business Week, August 1, 1994, Business and Industry, Section: Pg. 72;        https://doom.fandom.com/wiki/Trivia         https://www.doomworld.com/forum/topic/112509-share-your-epic-doom-related-stories/ Atari Games President passes     Play Meter, August 1994, pg. 32 Hasbro readies to enter VR market     No Headline In Original, ADWEEK, August 15, 1994, Eastern Edition, Byline: By Jennifer Comiteau and Penny Warneford, with Cathy Taylor        https://www.unseen64.net/2018/10/04/hasbro-toaster-virtual-reality-console/ Begone Project Reality, all hail Ultra 64     https://www.retromags.com/files/file/3018-egm2-issue-02-august-1994/  pg. 28      Sega teams up with Hitachi in Japan     HITACHI SALES TO HELP SEGA MARKET VIDEO GAMES, Jiji Press Ticker Service, AUGUST 3, 1994, WEDNESDAY             Sega, Hitachi Sales link up to sell video game machine, Japan Economic Newswire, AUGUST 3, 1994, WEDNESDAY Sega buys Cross Products     The leading video game development tool, Business Wire, August 15, 1994, Monday         https://segaretro.org/Cross_Products         https://web.archive.org/web/19961227100911/http://www.crossprod.co.uk/      Jaguar CD to launch by Xmas     https://www.retromags.com/files/file/3018-egm2-issue-02-august-1994/  pg. 29     ATARI CORP. ANNOUNCES SECOND QUARTER 1994 RESULTS, PR Newswire, August 1, 1994, Monday - 19:55 Eastern Time, Section: Financial News Sanyo gives console market a TRY     SANYO TO RELEASE INTERACTIVE GAME MACHINE TRY, Jiji Press Ticker Service, AUGUST 31, 1994, WEDNESDAY 3DO announces losses     Video Game System Company Posts $ 16.1 Million First-Quarter Loss, The Associated Press, August 11, 1994, Thursday, AM cycle, Section: Business News     COMPANY NEWS; SHARES OF 3DO SOAR ON FORECAST FOR NEW SYSTEM, The New York Times, August 24, 1994, Wednesday, Late Edition - Final, Distribution: Financial Desk, Section: Section D; ; Section D; Page 3; Column 1; Financial Desk ; Column 1;                3DO UNVEILS PLANS TO BOOST POWER OF GAME PLAYERS, WALL STREET JOURNAL, August 25, 1994, Thursday, Section: Section B; Page 8, Column 4, Byline: BY JIM CARLTON              ANOTHER KEY EXEC DEPARTS O&M'S, INTERACTIVE GROUP; 3DO POWERS UP TO MEET COMPETITION; INTERACTING:; OTHER NEWS: Advertising Age, August 29, 1994, Section: Pg. 14 Mortal Friday gets $10 million budget     ACCLAIM'S 'MORTAL KOMBAT II' PREPARED TO STRIKE ON 'MORTAL FRIDAY,' SEPTEMBER 9; Company Spending Over $10 Million on Global Launch, Business Wire, August 4, 1994, Thursday     https://archive.org/details/Computer_Gaming_World_Issue_121/page/n29/mode/2up Acclaim buys into FMV    Playthings, August 1994, pg. 19           https://archive.org/details/GamePro_Issue_061_August_1994/page/n157/mode/1up?view=theater Macromedia and Microware want to bring PCs and ITV together     Agreement to Make Computer Programs Available for Interactive TV Use, The Associated Press, August 1, 1994, Monday, AM cycle, Section: Business News, Byline: By STEVEN P. ROSENFELD, AP Business Writer       https://en.wikipedia.org/wiki/Macromedia        https://en.wikipedia.org/wiki/Microware      Computer industry profits boom     Not drowning, waving at profits, The Age (Melbourne, Australia), August 2, 1994 Tuesday, Late Edition, Section: COMPUTERS; Mass Storage; Pg. 34 SPA reports huge boom in sales     "NORTH AMERICAN PC SOFTWARE SALES REACH $1.48 BILLION, IN FIRST QUARTER 1994; HOME EDUCATION SALES LEAD GROWTH -- UP 128%, PR Newswire, August 8, 1994, Monday - 14:29 Eastern Time, Section: Financial News" CDRom bundles discouraging sales         Dataquest Consumer Survey Shows Where CD-ROM Title Developers Can Be Successful, Business Wire, August 8, 1994, Monday     Sirius Publishing to release long-awaited 5-ft. 10-Pak Volume II, Business Wire, August 8, 1994, Monday     https://archive.org/details/PC-Player-German-Magazine-1994-08/page/n15/mode/2up     https://archive.org/details/Electronic-Games-1994-08/page/14/mode/2up Flash memory prices tumbling     Not drowning, waving at profits, The Age (Melbourne, Australia), August 2, 1994 Tuesday, Late Edition, Section: COMPUTERS; Mass Storage; Pg. 34        https://en.wikipedia.org/wiki/Flash_memory Cyrix to take on AMD     Infoworld August 8, 1994, pg. 5 Employers begin to crackdown on games     Games they play, The Times, August 1, 1994, Monday, Section: Business, Byline: Jon Ashworth Microsoft targets "loosely supervised Executives"     SUNDAY, August 7, 1994; Playing Games at Work, The New York Times, August 7, 1994, Sunday, Late Edition - Final, Distribution: Magazine Desk, Section: Section 6; ; Section 6; Page 12; Column 1; Magazine Desk ; Column 1; MacPlay expands lineup     Playthings, August 1994, pg. 44 Ad game business booming in Germany     https://archive.org/details/PC-Player-German-Magazine-1994-08/page/n29/mode/2up Media Vision collapse profiled     https://archive.org/details/Electronic-Games-1994-08/page/10/mode/2up     https://archive.org/details/Electronic-Games-1994-08/page/12/mode/2up Victormaxx announces Cybermaxx     Virtual Reality Headset For PCs A Reality, Newsbytes News Network, August 5, 1994       http://videogamekraken.com/cybermaxx-by-victormaxx Mice go 3D     Echoes of Silicon Valley, Agence France Presse -- English, August 04, 1994 08:13 Eastern Time, Section: Domestic, non-Washington, general news item, Dateline: PALO ALTO, California, Aug 4         https://www.ebay.com/itm/304724946528 Microprose to bring Magic to PC         IT'S IN THE CARDS' FOR MICROPROSE(R) AND WIZARDS OF THE COAST(R);PR Newswire, August 10, 1994, Wednesday - 17:23 Eastern Time, Section: State and Regional News     https://www.mobygames.com/game/530/magic-the-gathering/        https://www.mobygames.com/game/6274/magic-the-gathering-battlemage/ Star Trek licenses are a mess     https://archive.org/details/Electronic-Games-1994-08/page/14/mode/2up TEN to bring SimCity online     Total Entertainment Network will feature online debut of popular SimCity, game, Business Wire, August 10, 1994, Wednesday      The web becomes a scary place     E-mail evil, The Jerusalem Post, August 4, 1994, Thursday, Section: OPINION; Pg. 6,  Byline: SANDY ROVNER Siliwood goes Online     DISNEY, AMERITECH, BELLSOUTH AND SOUTHWESTERN BELL PLAN ALLIANCE TO DEVELOP AND OFFER VIDEO SERVICES, PR Newswire, August 8, 1994, Monday - 13:31 Eastern Time, Section: Financial News Fujitsu brings habitat back to USA     Fujitsu to start 'cyberspace' game business in U.S., Japan Economic Newswire, AUGUST 10, 1994, WEDNESDAY Computer Porn outpacing UK lawmakers     https://archive.org/details/Atari_ST_User_Issue_103_1994-08_Europress_GB/page/n39/mode/2up Labor promises telecommunications reform     Party line for fun and games, The Times, August 5, 1994, Friday, Byline: Emma Woollacott        https://en.wikipedia.org/wiki/Mercury_Communications Interactive TV license purchasers default     SOME TOP BIDDERS AT AIRWAVE AUCTION FAILING TO PAY UP, Pittsburgh Post-Gazette (Pennsylvania), AUGUST 12, 1994, FRIDAY, SOONER EDITION, Section: BUSINESS, Byline: BLOOMBERG BUSINESS NEWS Acorn enters set top box market     https://archive.org/details/AcornUser145-Aug94/page/n7/mode/2up      Ziff Davis buys Compute     ZIFF-DAVIS ACQUIRES ASSETS OF COMPUTE MAGAZINE; COMPUTER LIFE AND FamilyPC'S ADVERTISERS TO GET UNEXPECTED BONUS CIRCULATION, PR Newswire, August 8, 1994, Monday - 19:06 Eastern Time Teenage reviewers on the rise     Teenage games writers get to call the shots, The Age (Melbourne, Australia), August 2, 1994 Tuesday, Late Edition, Section: COMPUTERS; Pg. 40, Byline: Amy Harmon Computer game book rights up for grabs     Book Notes, The New York Times, August 3, 1994, Wednesday, Late Edition - Final, Distribution: Cultural Desk, Section: Section C; ; Section C; Page 20; Column 5; Cultural Desk ; Column 5;,Byline: By Sarah Lyall         https://en.wikipedia.org/wiki/List_of_novels_based_on_video_games Disney gets MYST rights     Out of the 'Myst': Disney plays game for book, film; Hit CD-ROM software is going Hollywood, The Hollywood Reporter, August 11, 1994, Thursday, Byline: Scott Hettrick Stormfront to simulate strike season     PENDING BASEBALL STRIKE PROMPTS VIDEO GAME DEVELOPER TO PINCH HIT FOR REAL THING, PR Newswire, August 12, 1994, Friday - 09:02 Eastern Time, Section: Financial New          Real Unreal Baseball, The Associated Press, August 17, 1994, Wednesday, PM cycle, Section: Sports News, Byline: By JIM LITKE, AP Sports Writer     Indians overtake White Sox in AL Central; Braves, Expos torrid in Nintendo, Baseball League, Business Wire, August 21, 1994, Sunday Leonard Herman releases Phoenix     https://www.latimes.com/archives/la-xpm-1994-04-13-mn-45306-story.html  pg. 32      Nintendo ordered to pay $208 million     Nintendo U.S. unit told to pay 208 mil. dlrs in damages, Japan Economic Newswire, AUGUST 2, 1994, TUESDAY      https://archive.org/details/Electronic-Games-1994-08/page/14/mode/2up     No Headline in Original, Ad Day, August 8, 1994, Section: Corridor Talk Pg. 38, byline: Kevin Kerr Recommended Links: The History of How We Play: https://thehistoryofhowweplay.wordpress.com/ Gaming Alexandria: https://www.gamingalexandria.com/wp/ They Create Worlds: https://tcwpodcast.podbean.com/ Digital Antiquarian: https://www.filfre.net/ The Arcade Blogger: https://arcadeblogger.com/ Retro Asylum: http://retroasylum.com/category/all-posts/ Retro Game Squad: http://retrogamesquad.libsyn.com/ Playthrough Podcast: https://playthroughpod.com/ Retromags.com: https://www.retromags.com/ Games That Weren't - https://www.gamesthatwerent.com/ Sound Effects by Ethan Johnson of History of How We Play. Copyright Karl Kuras    

In this episode, Martin Witzenrath, MD, FERS, and Michele Bartoletti, MD, PhD, discuss the management of mild to moderate COVID-19 in patients who are immunocompromised, including:Initial workup, which may include laboratory tests and/or imagingLatest data on the use of remdesivir or nirmatrelvir plus ritonavir for mild to moderate COVID-19, including considerations for drug–drug interactions Presenters:Martin Witzenrath, MD, FERSMedical DirectorCharite Centrum 12Internal Medicine & DermatologyProfessor and Chair for Respiratory Medicine and Critical CareDepartment of Infectious Disease, Respiratory Medicine and Critical CareCharite Campus Mitte/Campus Virchow Klinikum/Campus Benjamin FranklinCharite – University of BerlinBerlin, GermanyMichele Bartoletti, MD, PhDAssociate Professor of Infectious DiseasesDepartment of Biomedical SciencesHumanitas UniversityPieve Emanuele (MI), ItalyHead of Infectious Diseases UnitIRCCS Humanitas Research HospitalRozzano (MI), Italy Link to full program: https://bit.ly/4gu2gcUDownloadable slides: https://bit.ly/3CGlDBSGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

In this episode, Stacey B. Trooskin, MD, PhD, MPH, Mark S. Sulkowski, MD, FIDSA, FAASLD, and Ronni Marks discuss hepatitis C virus (HCV) screening and treatment, focusing on people who use drugs, and highlight the following topics:Screening recommendationsStrategies to improve HCV screeningHCV testingTreatment goalsStrategies to improve HCV treatment uptakePresenters:Stacey B. Trooskin, MD, PhD, MPHExecutive Medical OfficerMazzoni CenterFaculty, University of PennsylvaniaPerelman School of MedicinePhiladelphia, PennsylvaniaMark S. Sulkowski, MD, FIDSA, FAASLDProfessor of MedicineDirector, Division of Infectious Diseases Johns Hopkins Bayview Medical CenterJohns Hopkins University School of MedicineBaltimore, MarylandRonni MarksFounder/Director, The Hepatitis C Mentor and Support Group (HCMSG)Patient AdvocateNew York, New YorkLink to full program:https://bit.ly/4grbwPT

In 2020, with funding from CDC, IDSA launched the Real-Time Learning Network, a website that provided timely information about COVID-19 pandemic to clinicians and the public. In this episode, medical editors of the Real-Time Learning Network recounts their experiences building the project from the ground up and lessons learned for the future.

In this episode of HIV unmuted, host Juan Michael Porter II sits down with Jeanne Marrazzo, the Director of the National Institute of Allergy and Infectious Diseases (NIAID), in a conversation that goes beyond the headlines and deep into the heart of HIV research and advocacy. Dr Marrazzo, a leader with decades of experience in infectious disease research, shares her inspiring journey from her roots in Scranton, Pennsylvania, to her groundbreaking work in HIV prevention and care. Through this intimate conversation, listeners will discover what drives Dr. Marrazzo's commitment to equity, diversity and community-centered research, and how her personal and professional experiences shape her vision for the future of HIV science. From the challenges of addressing global health inequities to the optimism surrounding new HIV prevention methods, Dr Marrazzo offers valuable insights into the importance of inclusive messaging, the power of collaboration, and why putting people first remains at the core of her mission. Tune in to hear how Jeanne Marrazzo plans to navigate the evolving landscape of global health as she leads NIAID into a new era, and why she believes that hope, innovation, and community are key to overcoming the ongoing challenges in the HIV response. Meet our guest: Jeanne Marrazzo   Jeanne Marrazzo, MD, MPH, FACP, FIDSA, is the Director of NIAID at the U.S. National Institutes of Health (NIH), where she oversees a USD 6.3 billion budget that supports research to advance understanding, diagnosis and treatment of infectious, immunologic and allergic diseases. She was previously the C. Glenn Cobbs Endowed Chair and Director of Infectious Diseases at the University of Alabama at Birmingham Heersink School of Medicine. She is a Fellow of the American College of Physicians and the Infectious Diseases Society of America (IDSA), and was Treasurer of the IDSA from 2021 to 2023, having served on the board since 2018. She researches the vaginal microbiome, sexually transmitted infections and HIV pre-exposure prophylaxis. She has had leadership roles in the NIH HIV Prevention Trials Network and the Infectious Diseases Clinical Research Consortium. She was a leading voice in communicating science during the COVID-19 pandemic.   Meet our host: Juan Michael Porter II  Juan Michael Porter II is a health journalist, HIV advocate, culture critic, educator and the host of HIV unmuted, the IAS podcast. He is the Senior Editor of TheBody.com and TheBodyPro – and the first person openly living with HIV to hold the position. Juan Michael's reportage combines data dives, personal narratives and policy analyses to address the real-world consequences of ever-shifting legislation on people's health outcomes. He has written for the Public Broadcasting Service, SF Chronicle, Philadelphia Inquirer, Christian Science Monitor, NY Observer, TDF Stages, Playbill, American Theatre, Time Out NY, Queerty, Anti-Racism Daily, Positively Aware, Documentary Magazine, SYFY Wire, Scholastic and Dance Magazine. 

In this episode of the Trust Issues podcast, host David Puner sits down with Jeff Reich, Executive Director of the Identity Defined Security Alliance (IDSA), a nonprofit that provides vendor-neutral guidance on identity-centric security strategies to help organizations reduce the risk of identity-related attacks. They explore the evolution of digital identity, discussing how it has transformed from simple identifiers to complex, multifaceted digital identities for both humans and machines. In today's threat landscape, the number and types of identities, attack methods and environments have dramatically increased, making it more challenging to secure identities. Jeff discusses the challenges and efforts in creating sustainable, interoperable digital identity hubs for cross-border applications, the future of digital passports and the importance of encryption and multi-factor authentication (MFA) for securing sensitive data. The conversation also highlights the significance of thought leadership and maintaining a vendor-agnostic approach in identity security.

Unfortunately, there simply isn't a one-size-fits-all treatment protocol for patients infected with Lyme disease and/or co-infections. This is why it's critical for physicians treating Lyme disease to invest time with patients, thoroughly understand their medical history, and closely monitor symptoms and treatment response. With that in mind, there are currently two different treatment approaches for Lyme disease. The Infectious Disease Society of America (IDSA) and the International Lyme and Associated Diseases Society (ILADS) have each published their own set of evidence-based treatment guidelines. IDSA guidelines recommend a short course of antibiotics, typically 14 to 30 days. IDSA argues that the Borrelia burgdorferi bacteria do not persist in a patient beyond this timeframe and that lingering symptoms are the result of an ongoing immune response and not an active infection. It also cites scientific evidence claiming treatments beyond 30 days are ineffective, unnecessary, and even dangerous. IDSA physicians will stop treatment after 30 days, even if symptoms remain. They advise an additional 30 days of treatment recommended for patients with Lyme arthritis.  On the contrary, ILADS offers its own scientific data to show that a additional treatment with antibiotics is required to eradicate the bacteria. ILADS recognizes that a month of treatment may be sufficient for patients in the acute stage of Lyme disease, but in cases where the spirochete has disseminated and the disease has advanced, a 30-day treatment regimen is inadequate. ILADS guidelines recommend additional antibiotics until a patient's symptoms have been resolved. Treating Lyme disease in its advanced stage can be complicated based on the complexity of the organism itself, differences in each patient's immune system, the length of time infected, and the possible presence of other co-infections transmitted by the same tick. There are several choices in treating Lyme disease, which include oral, intravenous, and intramuscular antibiotic options. Other options may include sequential antibiotic therapy, higher doses of antibiotics, taking antibiotics for a longer period of time, a combination of antibiotics, retreatment, as well as diagnosing and treating co-infections. Some specific antibiotics used in treating Lyme disease are doxycycline, minocycline, amoxicillin, cefuroxime, azithromycin, and clarithromycin. Other tests include measures of blood counts, chemistries, liver function tests, ANA, dsDNA, RF, TSH, free T3, free T4, ESR may be helpful at ruling out other conditions.  Referral to specialist might help to rule out other conditions.  I find shared decision with my patient helpful. I also find follow-up helpful to assess my patient's response to treatment to rule out other conditions. There are additional protocols that may also aid in treating Lyme disease, such as avoiding alcohol, simple and processed sugars, exercising as tolerated, counseling for a Jarisch-Herxheimer reaction, managing symptoms, monitoring and reducing the risk of an adverse event, and reducing stress. However, there is a chance of side effects such as Clostridium difficile-associated diarrhea (CDAD). Probiotic have been prescribed with the hope of reducing the risk of developing CDAD.   

Guest: Jeff Reich, Executive Director, Identity Defined Security Alliance [@idsalliance]On LinkedIn | https://www.linkedin.com/in/jreich/On Twitter | https://twitter.com/JeffReichCSO____________________________Hosts: Sean Martin, Co-Founder at ITSPmagazine [@ITSPmagazine] and Host of Redefining CyberSecurity Podcast [@RedefiningCyber]On ITSPmagazine | https://www.itspmagazine.com/sean-martinMarco Ciappelli, Co-Founder at ITSPmagazine [@ITSPmagazine] and Host of Redefining Society PodcastOn ITSPmagazine | https://www.itspmagazine.com/itspmagazine-podcast-radio-hosts/marco-ciappelli____________________________Episode NotesWelcome to this pre-event episode of On Location, where we're diving into what's to come at Identity Week Americas, happening September 11th and 12th, 2024, at the Washington Convention Center in D.C. Although I won't be on-site, Jeff—who leads the Identity Defined Security Alliance (IDSA)—gave me the inside scoop on why this event is one you can't afford to miss.Our conversation ranges from the critical role of digital identities and payments, to the pressing challenges facing the identity landscape today. Jeff shared insights on the panels he'll be participating in, like Interoperable Digital Identities and The Future of Payments, giving a preview of the big discussions that will take place at the event.We even touched on more serious global issues, such as the plight of refugees who lack identification, and how Identity Week is working toward solutions that can have a real impact. On top of that, the SIDI HUB Summit will run alongside the event, focusing on creating a standardized, globally recognized digital identity system.With Identity Week happening across multiple continents—from the Americas to Europe and Asia—the need for international collaboration has never been clearer. Jeff's vision for a globally interoperable identity system is ambitious, but the starting point is simple: practical steps like multi-factor authentication and building awareness about identity security.As we look forward to the event, Jeff also mentioned that there might still be some passes available for those interested in attending. Whether you're in the public sector, tech, or simply passionate about identity solutions, this event is your chance to get involved in shaping the future.Stay tuned for more coverage, and thanks for joining me on this pre-event journey as we explore what's in store at Identity Week Americas.Be sure to follow our Coverage Journey and subscribe to our podcasts!____________________________This Episode's SponsorsHITRUST: https://itspm.ag/itsphitweb____________________________Catch all of our event coverage: https://www.itspmagazine.com/technology-cybersecurity-society-humanity-conference-and-event-coverageOn YouTube:

Welcome! Today, we're exploring the key milestones in Lyme disease research and treatment.I had a 57-year-old patient who remained chronically ill after being diagnosed and treated for Lyme disease. He didn't realize that a persistent tick-borne infection could explain his chronic illness. He was treated with a combination of azithromycin and atovaquone for the persistent infection, and today, he is doing well.He was surprised that, despite the milestones in Lyme disease research, he wasn't aware that a persistent infection could lead to his chronic illness. So, let's take a closer look at these milestones.1. 1977: Discovery of Lyme DiseaseOur story begins in 1977 in Lyme, Connecticut. A cluster of children and adults were diagnosed with what was initially thought to be juvenile rheumatoid arthritis. This event marked the identification of Lyme disease as a distinct illness and the start of modern Lyme disease awareness."2. 1982: Discovery of the Bacterium Responsible for Lyme DiseaseIn 1982, Dr. Willy Burgdorfer identified Borrelia burgdorferi, the bacterium responsible for Lyme disease. This discovery was a major milestone, enabling more precise identification and treatment of the disease. 3. 1990: Recognition of Chronic Lyme DiseaseBy 1990, chronic Lyme disease, with its long-term and persistent symptoms, was officially recognized. This led to more comprehensive treatment protocols and increased awareness of the disease's chronic nature.4. 1995: Discovery of Babesia microtiIn 1995, Babesia microti was identified as a co-infection transmitted by the same ticks that carry Lyme disease. This highlighted the complexity of tick-borne illnesses and the need for integrated treatment approaches. 5. 2000: Publication of IDSA and ILADS GuidelinesThe year 2000 saw the publication of treatment guidelines by both the Infectious Disease Society of America (IDSA) and the International Lyme and Associated Diseases Society (ILADS). These guidelines showcased different approaches to treating Lyme disease, marking another significant milestone. 6. Ongoing Research and Future Milestones Research is ongoing, and we look forward to future milestones that could lead to breakthroughs in diagnosis and treatment. Studies on biofilms, persisters, and tick-borne co-infections may enable doctors to develop treatment plans that significantly improve patient outcomes.ConclusionUnderstanding these milestones helps us appreciate the progress made in the fight against Lyme disease. With continued research and dedication, we move closer to effective management and potential cures. Thank you for watching, and stay tuned for more insights on Lyme disease." 

IDSA Board member Mati Hlatshwayo Davis, MD, MPH, FIDSA, discusses the importance of advocacy, including how IDSA and HIVMA members can get involved, with chair and vice chair of IDSA's advocacy captain subcommittee, Rachel Bender Ignacio, MD, MPH, FIDSA, and Kinna Thakarar, DO, MPH, FIDSA, as well as IDSA senior vice president of public policy and government relations, Amanda Jezek, and HIVMA executive director, Andrea Weddle. General registration is now open for the premier ID meeting! Register for IDWeek for the opportunity to surround yourself with the ID experts who are advancing the field. Join ID professionals who want to stay current, apply state-of-the-art science to clinical care and excel in their own careers with CME/CPE/CNE/MOC credit available. Find your why and find your way to IDWeek, Oct. 16-19! https://idweek.org/registration/

Google agrees to delete billions of user records. NIST addresses the NVD backlog. India rescues hundreds of citizens from scam jobs in Cambodia. The UK and US agree to collaborate on AI safety. The FTC tracks an explosion in impersonation fraud. A PandaBuy breach exposes over 1.3 million customers. Prudential Financial informs over 36,000 customers of a data breach. A look at safeguarding sensitive data. Our guest is Jeff Reich, Executive Director of the Identity Defined Security Alliance (IDSA), with insights on identity security best practices. A dash of curiosity reveals a hotel chain vulnerability.  Remember to leave us a 5-star rating and review in your favorite podcast app. Miss an episode? Sign-up for our daily intelligence roundup, Daily Briefing, and you'll never miss a beat. And be sure to follow CyberWire Daily on LinkedIn. CyberWire Guest Guest Jeff Reich, Executive Director of the Identity Defined Security Alliance (IDSA), sharing insights on identity security best practices, identity and access sprawl, and how Generative AI is helping and hurting identity management. The IDSA's Identity Management Day 2024 is coming up on April 9, 2024. Selected Reading Google agreed to erase billions of browser records to settle a class action lawsuit (Security Affairs) Vulnerability database backlog due to increased volume, changes in 'support,' NIST says (The Record) India rescues 250 citizens enslaved by Cambodian cybercrime gang (Bleeping Computer) The US and UK are teaming up to test the safety of AI models (Engadget) Impersonation Scams Net Fraudsters $1.1bn in a Year ( Infosecurity Magazine) PandaBuy data breach allegedly impacted +1.3M customers (Security Affairs) Prudential Financial Data Breach Impacts 36,000 (SecurityWeek) How to bridge the gap between the IT and legal staffs to better combat insider risk (SC Media) IBIS hotel check-in terminal keypad-code leakage (Pentagrid AG) Share your feedback. We want to ensure that you are getting the most out of the podcast. Please take a few minutes to share your thoughts with us by completing our brief listener survey as we continually work to improve the show.  Want to hear your company in the show? You too can reach the most influential leaders and operators in the industry. Here's our media kit. Contact us at cyberwire@n2k.com to request more info. The CyberWire is a production of N2K Networks, your source for strategic workforce intelligence. © 2023 N2K Networks, Inc.